Moderna, a biotech giant that gained prominence during the COVID-19 pandemic, has revolutionized the biotechnology domain.

Moderna (NASDAQ:MRNA) shares traded in the green on Friday, snapping six consecutive days of losses. The stock closed up 0.55 ...

Shares of Moderna Inc. MRNA inched 0.55% higher to $53.09 Friday, on what proved to be an all-around mixed trading session ...

Northwestern filed a lawsuit against Moderna Wednesday alleging the company misused the University’s patented lipid ...

Moderna was hit with a new patent lawsuit on Wednesday in Delaware federal court from Northwestern University, which accused ...

Moderna is focusing on respiratory vaccines to sustain revenue streams amid COVID-19 declines. See more on MRNA stock and its ...

Despite giving the world one of the first and most widely used COVID-19 vaccines, shares of Moderna MRNA have lost ...

A WhatsApp message has earned Moderna a reprimand from the UK's Prescription Medicines Code of Practice Authority (PMCPA), ...

For a drugmaker advancing medicines through clinical trials, time is the enemy: the longer the process takes, the more costs ...

Many people don’t know they’re eligible. | Moderna has identified a fundamental barrier to vaccination: many people don’t ...

The biotech industry is buzzing with exciting changes, and a lot of it is thanks to one company: Moderna. Known for its COVID ...

UBS lowered the firm’s price target on Moderna (MRNA) to $108 from $140 and keeps a Buy rating on the shares following a model review.